Klin Farmakol Farm. 2011;25(1):35-40

Influence of oral antidiabetic agents on endothelial dysfunction

Veronika Drobná1, Stanislava Jankyová2, Jana Tisoňová1, Andrej Dukát3, Viera Kristová1, Agáta Mačugová1, Lenka Kostková1, Martin Wawruch1
1 Ústav farmakológie a klinickej farmakológie, LF UK, Bratislava
2 Katedra farmakológie a toxikológie, FaF UK, Bratislava
3 II. interná klinika, LF UK a FNsP, Bratislava

Vascular damage represents the most frequent complication of diabetes mellitus (DM). Therefore therapy of DM should be focused not

only on the adjustment of blood glucose level, but also on the prevention and treatment of vascular damage. Some of currently used

antidiabetic agents show endothelium-protective properties that are not directly linked to their glucose-lowering effect. They represent

promising tools for the reduction of cardiovascular morbidity and mortality in patients suffering from DM. This paper characterizes

individual groups of antidiabetic agents regarding their influence on endothelial dysfunction in patients with type 2 DM.

Keywords: antidiabetics, endothelial dysfunction, diabetes mellitus

Published: March 18, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Drobná V, Jankyová S, Tisoňová J, Dukát A, Kristová V, Mačugová A, et al.. Influence of oral antidiabetic agents on endothelial dysfunction. Klin Farmakol Farm. 2011;25(1):35-40.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. http://www.who.int/mediacentre/factsheets/fs312/en/, 13. 12. 2010.
    2. Macfarlane DP, Paterson KR, Fisher M. Oral antidiabetic agents as cardiovascular drugs. Diab Obes Metab 2007; 9: 23-30. Go to original source... Go to PubMed...
    3. Grover-Páez F, Zavalza-Gómez AB. Endothelial dysfunction and cardiovascular risk factors. Diab Res Clin Pr 2009; 84: 1-10. Go to original source... Go to PubMed...
    4. De Vriese AS, Verbeuren TJ, de Voorde JV, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Brit J Pharmacol 2000; 130: 963-974. Go to original source... Go to PubMed...
    5. Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease. Circulation 2006; 113: 1708-1714. Go to original source... Go to PubMed...
    6. Goh SY, Cooper ME. The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocr Metab 2008; 93: 1143-1152. Go to original source... Go to PubMed...
    7. Tabit CE, Chung WB, Hamburg NM, Vita JA. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord. 2010; 11: 61-74. Go to original source... Go to PubMed...
    8. Cersosimo E, DeFronzo R. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res 2006; 22: 423-436. Go to original source... Go to PubMed...
    9. http://www.heartscore.org/Pages/Scientificbg.aspx, 15. 12. 2010.
    10. Graham IM. The importance of total cardiovascular risk assessment in clinical practice. Eur J Gen Pract 2006; 12: 148-155. Go to original source... Go to PubMed...
    11. TerAvest E, Stalenhoef AFH, de Graaf J. What is the role of non-invasive measurements of atherosclerosis in individual cardiovascular risk prediction? Clin Sci 2007; 112: 507-516. Go to original source... Go to PubMed...
    12. Ribeiro F, Alves AJ, Teixeira M, Ribeiro V, Duarte JA, Oliveira J. Endothelial function and atherosclerosis: circulatory markers with clinical usefulness. Rev Port Cardiol. 2009; 28: 1121-1151. Go to PubMed...
    13. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994; 24: 1468-1474. Go to original source... Go to PubMed...
    14. Wackers FJ, Young LH, Inzucchi SE, et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 2004; 27: 1954-1961. Go to original source... Go to PubMed...
    15. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes II. Mortality results. Diabetes 1970; 19: 789-830.
    16. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853. Go to original source...
    17. Noda Y, Mori A, Packer L. Gliclazide scavenges hydroxyl, superoxide and nitric oxide radicals: an ESR study. Res Commun Mol Pathol Pharmacol 1997; 96: 115-124. Go to PubMed...
    18. Jennings PE, Belch JJ. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide. Metabolism. 2000; 49: 23-26. Go to original source... Go to PubMed...
    19. O'Brien RC, Luo M, Balazs N, Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications 2000; 14: 201-206. Go to original source... Go to PubMed...
    20. Renier G, Desfaits AC, Serri O. Gliclazide decreases lowdensity lipoprotein oxidation and monocyte adhesion to the endothelium. Metabolism 2000; 49: 17-22. Go to original source... Go to PubMed...
    21. Chugh SN, Dhawan R, Kishore K, Sharma A, Chugh K. Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus - a double blind randomized study. J Assoc Physicians India 2001; 49: 803-807. Go to PubMed...
    22. Gram J, Jespersen J. Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients. Am J Med 1991; 90: 62-66. Go to original source... Go to PubMed...
    23. Konya H, Hasegawa Y, Hamaguchi T, et al. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus. Metabolism 2010; 59: 1294-1299. Go to original source... Go to PubMed...
    24. Akanuma Y, Kosaka K, Kanazawa Y, Kasuga M, Fukuda M, Aoki S. Diabetic retinopathy in non-insulin-dependent diabetes mellitus patients: the role of gliclazide. Am J Med 1991; 90: 74-76. Go to original source... Go to PubMed...
    25. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572. Go to original source... Go to PubMed...
    26. Calderone V, Rapposelli S, Martelli A, et al. NO-glibenclamide derivatives: Prototypes of a new class of nitric oxidereleasing anti-diabetic drugs. Bioorganic Med Chem 2009; 17: 5426-5432. Go to original source... Go to PubMed...
    27. Rizzo MR, Barbieri M, Grella R, Passariello N, Paolisso G. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. Diabetes Metab 2005; 31: 255-260. Go to original source... Go to PubMed...
    28. Schmoelzer I, Wascher TC. Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance. Cardiovasc Diabetol 2006; 5: 9. Go to original source... Go to PubMed...
    29. Mita T, Watada H, Shimizu T, et al. Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. Arterioscler Thromb Vasc Biol 2007; 27: 2456-2462. Go to original source... Go to PubMed...
    30. NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1463-1476. Go to original source... Go to PubMed...
    31. Buse JB, Tan MH, Prince MJ, Erickson PP. The effects of oral antihyperglycaemic medications on serum lipid profiles in patients with type 2 Diabetes. Diabetes Obes Metab 2004; 6: 133-156. Go to original source... Go to PubMed...
    32. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865. Go to original source...
    33. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-2248. Go to original source... Go to PubMed...
    34. Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006; 49: 930-936. Go to original source... Go to PubMed...
    35. Orio F, Palomba S, Cascella T, et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab 2005; 90: 6072-6076. Go to original source... Go to PubMed...
    36. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001; 37: 1344-1350. Go to original source... Go to PubMed...
    37. de Aguiar LG, Bahia LR, Villela N, et al. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 2006; 29: 1083-1089. Go to original source...
    38. Asagami T, Abbasi F, Stuelinger M, et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2002; 51: 843-846. Go to original source... Go to PubMed...
    39. Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AMPactivated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 2006; 55: 496-505. Go to original source... Go to PubMed...
    40. Beisswenger P, Ruggiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab 2003; 29: 95-103. Go to original source... Go to PubMed...
    41. Mamputu JC, Wiernsperger NF, Renier G. Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab 2003; 29: 71-76. Go to original source... Go to PubMed...
    42. Bailey CJ. Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther 2008; 22: 215-224. Go to original source... Go to PubMed...
    43. Forst T, Lübben G, Hohberg C, et al. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation 2005; 12: 543-550. Go to original source... Go to PubMed...
    44. Quinn CE, Lockhart CJ, Hamilton PK, Loughrey CM, McVeigh GE. Effect of pioglitazone on endothelial function in impaired glucose tolerance. Diabetes Obes Metab 2010; 12: 709-715. Go to original source... Go to PubMed...
    45. Walcher T, Walcher D, Hetzel J, et al. Rapid effect of single-dose rosiglitazone treatment of endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study. Diab Vasc Dis Res 2010; 7: 178-185. Go to original source... Go to PubMed...
    46. Pop-Busui R, Oral E, Raffel D, et al. Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus. Metabolism 2009; 58: 989-994. Go to original source... Go to PubMed...
    47. Kotchen TA, Zhang HY, Reddy S, Hoffmann RG. Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am J Physiol 1996; 270: 660-666. Go to original source... Go to PubMed...
    48. Aljada A, Garg R, Ghanim H, et al. Nuclear factor-?B suppresive and inhibitor-?B stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an anti-inflammatory action. J Clin Endocrinol Metab 2001; 86: 3250-3256. Go to original source...
    49. Dandona P, Aljada A. Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents. J Diabetes Complications 2004; 18: 91-102. Go to original source... Go to PubMed...
    50. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471. Go to original source... Go to PubMed...
    51. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135. Go to original source... Go to PubMed...
    52. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289. Go to original source... Go to PubMed...
    53. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180-1188. Go to original source... Go to PubMed...
    54. Wascher TC, Schmoelzer I, Wiegratz A, et al. Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur J Clin Invest 2005; 35: 551-557. Go to original source... Go to PubMed...
    55. Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 2006; 91: 837-842. Go to original source... Go to PubMed...
    56. Kato T, Inoue T, Node K. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol 2010; 9: 12. Go to original source... Go to PubMed...
    57. Pistrosch F, Schaper F, Passauer J, Koehler C, Bornstein SR, Hanefeld M. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes. Horm Metab Res 2009; 41: 104-108. Go to original source... Go to PubMed...
    58. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-494. Go to original source... Go to PubMed...
    59. Hanefeld M. Treatment of impaired glucose tolerance with acarbose and its effect on intima-media thickness: a substudy of the STOP-NIDDM trial (study to prevent noninsulin-dependent diabetes mellitus). Endocr Pract 2006; 12: 56-59. Go to original source... Go to PubMed...
    60. van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28: 154-163. Go to original source... Go to PubMed...
    61. Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol 2009; 201: 59-66. Go to original source... Go to PubMed...
    62. Courr?ges JP, Vilsb?ll T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med 2008; 25: 1129-1131. Go to original source... Go to PubMed...
    63. Nystrom T, Gutniak MK, Zhang Q, et al. Effects of gucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2007; 293: 1289-1295.
    64. Sjoholm A. Impact of glucagon-like peptide-1 on endothelial function. Diab Obes Metab 2009; 11: 19-25. Go to original source... Go to PubMed...
    65. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436-447. Go to original source... Go to PubMed...
    66. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006; 12: 694-699. Go to original source... Go to PubMed...
    67. Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010; 33: 1607-1609. Go to original source... Go to PubMed...
    68. Anderson SL, Trujillo JO. Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann Pharmacother 2010; 44: 904-909. Go to PubMed...
    69. Kassem SA, Raz I. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No. Diabetes Care. 2009; 32: 337-341. Go to original source... Go to PubMed...
    70. Bianchi C, Miccoli R, Daniele G, Penno G, Del Prato S. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. Diabetes Care. 2009; 32: 342-348. Go to original source... Go to PubMed...
    71. Kar P, Holt RI. The effect of sulphonylureas on the microvascular and macrovascular complications of diabetes. Cardiovasc Drugs Ther 2008; 22: 207-213. Go to original source... Go to PubMed...
    72. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705. Go to original source... Go to PubMed...
    73. Uwaifo GI, Ratner RE. Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk. Am J Cardiol 2007; 99: 51-67. Go to original source... Go to PubMed...
    74. Gallwitz B. The evolving place of incretin-based therapies in type 2 diabetes. Pediatr Nephrol 2010; 25: 1207-1217. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.